Michael Morabito, PhD is a seasoned biotechnology industry professional with expertise in diverse therapeutic areas of Immuno-Oncology, Metabolic Diseases, Diabetes, and Alzheimer’s Disease, among others. He is currently a Senior Research Analyst - SMid-Cap Biotechnology at Chardan, where he leverages his years of experience in investment banking and equity research to analyze and provide insights on medical organizations. Michael has also worked as a Vice President Equity Research and Equity Research Analyst at Credit Suisse in the past. His vast scientific knowledge and experience have been honed by his Post-doctoral Fellow/Graduate Student position at Vanderbilt University Medical Center, where he obtained his Ph.D. degree in Neuroscience. Combined with his Bachelor's Degree in Biology, General from the University of Virginia, Michael has amassed an impressive background in the healthcare and life sciences domain. Furthermore, his interests span multiple therapeutic areas such as rare genetic diseases, cardiology, pharmacology, behavioral disorders, endocrinology, and more.